1
Guriq Basi, Jose William Saldanha: Humanized antibodies that recognize beta amyloid peptide. Neuralab, Wyeth, Lahive & Cockfield, Amy E Mandragouras, Debra J Milasincic, February 20, 2007: US07179892 (72 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.


2
Guriq Basi, Jose Saldanha: Humanized antibodies that recognize beta amyloid peptide. Elan Pharma International, Wyeth, Lahive & Cockfield, Amy E Mandragouras Esq, Debra J Milasincic Esq, August 14, 2007: US07256273 (60 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.


3
Basi Guriq, Saldanha Jose W, Bard Frédérique: Humanized antibodies that recognize beta amyloid peptide. Neuralab, Wyeth, Basi Guriq, Saldanha Jose W, Bard Frédérique, MILASINCIC Debra J, December 16, 2004: WO/2004/108895 (60 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aß in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.


4
Guriq Basi, Jose William Saldanha: Humanized antibodies that recognize beta amyloid peptide. Wyeth, Neuralab, Lahive & Cockfield, Amy E Mandragouras Esq, Debra J Milasincic Esq, March 13, 2007: US07189819 (48 worldwide citation)

The invention provides improves agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.


5
Basi Guriq, Jacobsen Jack Steven: Humanized antibodies that recognize beta amyloid peptide. Neuralab, Wyeth, Basi Guriq, Jacobsen Jack Steven, MILASINCIC Debra J, June 22, 2006: WO/2006/066049 (36 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&bgr; in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.


6
Basi Guriq, Saldanha Jose W, Yednock Ted: Humanized antibodies that recognize beta amyloid peptide. Neuralab, Wyeth, Basi Guriq, Saldanha Jose W, Yednock Ted, MANDRAGOURAS Amy E, September 23, 2004: WO/2004/080419 (36 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&bgr; in the brain of a patient. Preferred agents include humanized antibodies.


7
Guriq Basi, Jack Steven Jacobsen: Humanized antibodies that recognize beta amyloid peptide. Janssen Alzheimer Immunotherapy, Townsend and Townsend and Crew, December 1, 2009: US07625560 (31 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.


8
Guriq Basi, Jose William Saldanha: Humanized antibodies that recognize beta amyloid peptide. Elan Pharma International, Wyeth, Townsend and Townsend and Crew, September 1, 2009: US07582733 (24 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.


9
Guriq Basi, Jose Saldanha, Frédérique Bard: Humanized antibodies that recognize beta amyloid peptide. Janssen Alzheimer Immunotherapy, Wyeth, Alston and Bird, January 18, 2011: US07871615 (14 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.


10
Dale B Schenk: Humanized antibodies that recognize beta amyloid peptide. Janssen Alzheimer Immunotherapy, Alston & Bird, February 22, 2011: US07893214 (13 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.